[The management of patients with heparin-induced thrombocytopenia].
Heparin-induced thrombocytopenia is a strong risk factor for the development of arterial and venous thromboembolic events. In patients clinically suspected for HIT, immediate cessation of heparin treatment and continuation of anticoagulant treatment using alternative anticoagulants is mandatory in order to minimize the risk of thrombotic events. Alternative anticoagulants that have been successfully used in HIT include the direct acting thrombin inhibitors hirudin, bivalirudin and argatroban, and the heparinoid orgaran. In addition, there is growing evidence that the synthetic pentasaccharide fondaparinux is usable for the treatment of HIT patients. This short review summarizes the strategies of alternate anticoagulant treatment in HIT patients and also describes long-term treatment of HIT patients.
Pötzsch
B
B
Institut für Experimentelle Hämatologie und Transfusionsmedizin, Sigmund-Freud-Str. 25, 53105 Bonn. bernd.poetzsch@ukb.uni-bonn.de
Madlener
K
K
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000628:therapy*; D013923:Thromboembolism / Q000139:chemically induced* / Q000628:therapy*
D000925:Anticoagulants; D006493:Heparin